236 related articles for article (PubMed ID: 31344429)
1. Sclareol is a potent enhancer of doxorubicin: Evaluation of the free combination and co-loaded nanostructured lipid carriers against breast cancer.
Borges GSM; Silva JO; Fernandes RS; de Souza ÂM; Cassali GD; Yoshida MI; Leite EA; de Barros ALB; Ferreira LAM
Life Sci; 2019 Sep; 232():116678. PubMed ID: 31344429
[TBL] [Abstract][Full Text] [Related]
2. Improved Cytotoxic Effect of Doxorubicin by Its Combination with Sclareol in Solid Lipid Nanoparticle Suspension.
Oliveira MS; Lima BHS; Goulart GAC; Mussi SV; Borges GSM; Oréfice RL; Ferreira LAM
J Nanosci Nanotechnol; 2018 Aug; 18(8):5609-5616. PubMed ID: 29458616
[TBL] [Abstract][Full Text] [Related]
3. Co-delivery of doxorubicin, docosahexaenoic acid, and α-tocopherol succinate by nanostructured lipid carriers has a synergistic effect to enhance antitumor activity and reduce toxicity.
Lages EB; Fernandes RS; Silva JO; de Souza ÂM; Cassali GD; de Barros ALB; Miranda Ferreira LA
Biomed Pharmacother; 2020 Dec; 132():110876. PubMed ID: 33113428
[TBL] [Abstract][Full Text] [Related]
4. pH-sensitive doxorubicin-tocopherol succinate prodrug encapsulated in docosahexaenoic acid-based nanostructured lipid carriers: An effective strategy to improve pharmacokinetics and reduce toxic effects.
Lages EB; Fernandes RS; Andrade MMS; Paiyabhroma N; de Oliveira RB; Fernandes C; Cassali GD; Sicard P; Richard S; Branco de Barros AL; Ferreira LAM
Biomed Pharmacother; 2021 Dec; 144():112373. PubMed ID: 34794238
[TBL] [Abstract][Full Text] [Related]
5. α- Tocopherol succinate loaded nano-structed lipid carriers improves antitumor activity of doxorubicin in breast cancer models in vivo.
Fernandes RS; Silva JO; Seabra HA; Oliveira MS; Carregal VM; Vilela JMC; Andrade MS; Townsend DM; Colletti PM; Leite EA; Cardoso VN; Ferreira LAM; Rubello D; Barros ALB
Biomed Pharmacother; 2018 Jul; 103():1348-1354. PubMed ID: 29864917
[TBL] [Abstract][Full Text] [Related]
6. Lung cancer combination therapy: co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect.
Wang Y; Zhang H; Hao J; Li B; Li M; Xiuwen W
Drug Deliv; 2016 May; 23(4):1398-403. PubMed ID: 26079530
[TBL] [Abstract][Full Text] [Related]
7. The anti-tumor and renoprotection study of E-[c(RGDfK)
Zhang B; Zhang Y; Dang W; Xing B; Yu C; Guo P; Pi J; Deng X; Qi D; Liu Z
J Nanobiotechnology; 2022 Sep; 20(1):425. PubMed ID: 36153589
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy.
Fernandes RS; Silva JO; Monteiro LOF; Leite EA; Cassali GD; Rubello D; Cardoso VN; Ferreira LAM; Oliveira MC; de Barros ALB
Biomed Pharmacother; 2016 Dec; 84():252-257. PubMed ID: 27664949
[TBL] [Abstract][Full Text] [Related]
9. Which one performs better for targeted lung cancer combination therapy: pre- or post-bombesin-decorated nanostructured lipid carriers?
Du J; Li L
Drug Deliv; 2016 Jun; 23(5):1799-809. PubMed ID: 26455787
[TBL] [Abstract][Full Text] [Related]
10. Combined photothermal-chemotherapy of breast cancer by near infrared light responsive hyaluronic acid-decorated nanostructured lipid carriers.
Zheng S; Nguyen VD; Song SY; Han J; Park JO
Nanotechnology; 2017 Oct; 28(43):435102. PubMed ID: 28783035
[TBL] [Abstract][Full Text] [Related]
11. Nanostructured Lipid Carrier Co-loaded with Doxorubicin and Docosahexaenoic Acid as a Theranostic Agent: Evaluation of Biodistribution and Antitumor Activity in Experimental Model.
Fernandes RS; Silva JO; Mussi SV; Lopes SCA; Leite EA; Cassali GD; Cardoso VN; Townsend DM; Colletti PM; Ferreira LAM; Rubello D; de Barros ALB
Mol Imaging Biol; 2018 Jun; 20(3):437-447. PubMed ID: 29043471
[TBL] [Abstract][Full Text] [Related]
12. Targeted delivery of doxorubicin into tumor cells by nanostructured lipid carriers conjugated to anti-EGFRvIII monoclonal antibody.
Abdolahpour S; Toliyat T; Omidfar K; Modjtahedi H; Wong AJ; Rasaee MJ; Kashanian S; Paknejad M
Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):89-94. PubMed ID: 28296511
[TBL] [Abstract][Full Text] [Related]
13. Lung cancer combination therapy: doxorubicin and β-elemene co-loaded, pH-sensitive nanostructured lipid carriers.
Cao C; Wang Q; Liu Y
Drug Des Devel Ther; 2019; 13():1087-1098. PubMed ID: 31118562
[No Abstract] [Full Text] [Related]
14. Liposomes co-encapsulating doxorubicin and glucoevatromonoside derivative induce synergic cytotoxic response against breast cancer cell lines.
Novais MVM; Gomes ER; Miranda MC; Silva JO; Gomes DA; Braga FC; Pádua RM; Oliveira MC
Biomed Pharmacother; 2021 Apr; 136():111123. PubMed ID: 33486211
[TBL] [Abstract][Full Text] [Related]
15. Transferrin-modified nanostructured lipid carriers as multifunctional nanomedicine for codelivery of DNA and doxorubicin.
Han Y; Zhang Y; Li D; Chen Y; Sun J; Kong F
Int J Nanomedicine; 2014; 9():4107-16. PubMed ID: 25187713
[TBL] [Abstract][Full Text] [Related]
16. Antitumor and Anti-Metastatic Effects of Citral-Loaded Nanostructured Lipid Carrier in 4T1-Induced Breast Cancer Mouse Model.
Nordin N; Yeap SK; Rahman HS; Zamberi NR; Mohamad NE; Abu N; Masarudin MJ; Abdullah R; Alitheen NB
Molecules; 2020 Jun; 25(11):. PubMed ID: 32526880
[TBL] [Abstract][Full Text] [Related]
17. Co-delivery of baicalein and doxorubicin by hyaluronic acid decorated nanostructured lipid carriers for breast cancer therapy.
Liu Q; Li J; Pu G; Zhang F; Liu H; Zhang Y
Drug Deliv; 2016 May; 23(4):1364-8. PubMed ID: 25874959
[TBL] [Abstract][Full Text] [Related]
18. Co-delivery of Doxorubicin and Curcumin with Polypeptide Nanocarrier for Synergistic Lymphoma Therapy.
Guo W; Song Y; Song W; Liu Y; Liu Z; Zhang D; Tang Z; Bai O
Sci Rep; 2020 May; 10(1):7832. PubMed ID: 32398729
[TBL] [Abstract][Full Text] [Related]
19. Bacterial cellulose hydrogel loaded with lipid nanoparticles for localized cancer treatment.
Cacicedo ML; Islan GA; León IE; Álvarez VA; Chourpa I; Allard-Vannier E; García-Aranda N; Díaz-Riascos ZV; Fernández Y; Schwartz S; Abasolo I; Castro GR
Colloids Surf B Biointerfaces; 2018 Oct; 170():596-608. PubMed ID: 29975908
[TBL] [Abstract][Full Text] [Related]
20. Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy.
Li X; Jia X; Niu H
Int J Nanomedicine; 2018; 13():4107-4119. PubMed ID: 30034236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]